CLX Stock Analysis: The Clorox | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 9.724m USD | 12M Return: -26.9% | US1890541097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 259M
EPS Trend: 38.8%
Qual. Beats: 0
Rev. Trend: -75.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a multinational manufacturer and marketer of consumer and professional products. The company organizes its operations into four segments: Health and Wellness, Household, Lifestyle, and International, distributing goods across both retail and institutional channels worldwide.
Clorox operates a brand-heavy business model built around a portfolio of iconic household names spanning cleaning and disinfecting products (Clorox, Pine-Sol, Tilex, Formula 409), professional hygiene solutions (Purell, GOJO, CloroxPro), waste and food protection (Glad, Chux, Hidden Valley), pet care (Fresh Step, Scoop Away, Ever Clean), grilling (Kingsford), and natural personal care and water filtration (Burts Bees, Brita). Its products reach consumers through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet, and military stores, as well as e-commerce and direct sales distributors.
As a member of the Consumer Staples sector under the Household Products sub-industry, Clorox benefits from the typically defensive nature of its category, with demand for cleaning, disinfecting, and food-related essentials generally remaining stable through economic cycles. The companys reliance on a wide network of U.S. mass-market retailers makes shelf placement and retailer relationships central to its competitive position.
- Disinfecting category volumes decline as pandemic demand normalizes
- Commodity and pulp input costs pressure gross margins
- International sales face emerging market currency headwinds
| Net Income: 587.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -8.49 > 1.0 |
| NWC/Revenue: -14.12% < 20% (prev -4.38%; Δ -9.74% < -1%) |
| CFO/TA 0.08 > 3% & CFO 612.0m > Net Income 587.0m |
| Net Debt (5.83b) to EBITDA (1.17b): 4.99 < 3 |
| Current Ratio: 0.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.1m) vs 12m ago -1.30% < -2% |
| Gross Margin: 42.32% > 18% (prev 45.23%; Δ -2.91% > 0.5%) |
| Asset Turnover: 100.6% > 50% (prev 127.7%; Δ -27.11% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBIT TTM 921.0m / Interest Expense TTM 130.0m) |
| A: -0.12 (Total Current Assets 1.82b - Total Current Liabilities 2.77b) / Total Assets 7.79b |
| B: 0.05 (Retained Earnings 386.0m / Total Assets 7.79b) |
| C: 0.14 (EBIT TTM 921.0m / Avg Total Assets 6.68b) |
| D: 0.01 (Book Value of Equity 90.0m / Total Liabilities 7.54b) |
| Altman-Z'' = 0.30 = B |
| DSRI: 1.02 (Receivables 791.0m/821.0m, Revenue 6.72b/7.10b) |
| GMI: 1.07 (GM 45.23% / 42.32%) |
| AQI: 1.23 (AQ_t 0.52 / AQ_t-1 0.42) |
| SGI: 0.95 (Revenue 6.72b / 7.10b) |
| TATA: -0.00 (NI 587.0m - CFO 612.0m) / TA 7.79b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 83.80 with a total of 1,496,915 shares traded. Over the past week, the price has changed by +4.22%, over one month by -6.49%, over three months by -8.91% and over the past year by -26.91%.
Current recommended Stop Loss: 80.40 (which is 4.1% or 1.4 ATR below the current price).
The Clorox has received a consensus analysts rating of 2.78. Therefore, it is recommended to hold CLX.
- StrongBuy: 1
- Buy: 0
- Hold: 13
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 100.1 | 19.4% |
P/E Trailing = 16.7173
P/E Forward = 14.9477
P/S = 1.447
P/B = 117.1015
P/EG = 1.0911
Revenue TTM = 6.72b USD
EBIT TTM = 921.0m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 3.98b USD (from longTermDebt, last quarter)
Short Term Debt = 1.17b USD (from shortTermDebt, last quarter)
Debt = 5.97b USD (from shortLongTermDebtTotal, last quarter) + Leases 452.0m
Net Debt = 5.83b USD (calculated: Debt 5.97b - CCE 143.0m)
Enterprise Value = 15.6b USD (9.72b + Debt 5.97b - CCE 143.0m)
Interest Coverage Ratio = 7.08 (Ebit TTM 921.0m / Interest Expense TTM 130.0m)
EV/FCF = 38.40x (Enterprise Value 15.6b / FCF TTM 405.0m)
FCF Yield = 2.60% (FCF TTM 405.0m / Enterprise Value 15.6b)
FCF Margin = 6.03% (FCF TTM 405.0m / Revenue TTM 6.72b)
Net Margin = 8.74% (Net Income TTM 587.0m / Revenue TTM 6.72b)
Gross Margin = 42.32% ((Revenue TTM 6.72b - Cost of Revenue TTM 3.88b) / Revenue TTM)
Gross Margin QoQ = 41.27% (prev 43.23%)
Tobins Q-Ratio = 2.00 (Enterprise Value 15.6b / Total Assets 7.79b)
Interest Expense / Debt = 2.18% (Interest Expense 130.0m / Debt 5.97b)
Taxrate = 24.02% (190.0m / 791.0m)
NOPAT = 699.8m (EBIT 921.0m * (1 - 24.02%))
Current Ratio = 0.66 (Total Current Assets 1.82b / Total Current Liabilities 2.77b)
Debt / Equity = 66.36 (Debt 5.97b / totalStockholderEquity, last quarter 90.0m)
Debt / EBITDA = 4.99 (Net Debt 5.83b / EBITDA 1.17b)
Debt / FCF = 14.39 (Net Debt 5.83b / FCF TTM 405.0m)
Total Stockholder Equity = 49.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.79% (Net Income 587.0m / Total Assets 7.79b)
RoE = 1.20k% (out of range, set to none) (Net Income TTM 587.0m / Total Stockholder Equity 49.0m)
RoCE = 22.85% (EBIT 921.0m / Capital Employed (Equity 49.0m + L.T.Debt 3.98b))
RoIC = 11.56% (NOPAT 699.8m / Invested Capital 6.05b)
WACC = 4.73% (E(9.72b)/V(15.7b) * Re(6.62%) + D(5.97b)/V(15.7b) * Rd(2.18%) * (1-Tc(0.24)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.92 | Cagr: -0.76%
[DCF] Terminal Value 73.10% ; FCFF base≈547.4m ; Y1≈480.0m ; Y5≈387.8m
[DCF] Fair Price = 3.28 (EV 6.23b - Net Debt 5.83b = Equity 396.4m / Shares 120.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 38.80 | EPS CAGR: 6.18% | SUE: 0.08 | # QB: 0
Revenue Correlation: -75.91 | Revenue CAGR: -2.84% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.09 | Chg30d=-1.44% | Revisions=-64% | Analysts=15
EPS next Quarter (2026-12-31): EPS=1.34 | Chg30d=-2.09% | Revisions=-64% | Analysts=15
EPS current Year (2027-06-30): EPS=5.78 | Chg30d=-0.47% | Revisions=-53% | GrowthEPS=+4.5% | GrowthRev=+13.6%
EPS next Year (2028-06-30): EPS=6.25 | Chg30d=-0.54% | Revisions=-40% | GrowthEPS=+8.2% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: -70% (up=5, down=35)